Physician profile
Patrick Alan Whitman
NPI 1841758810
$9,167.20
in general payments reported to CMS, 2019-2025
27 companies · $1,838 in 2025
The $1,838 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $151 · 2021: $1,677 · 2022: $1,592 · 2023: $1,770 · 2024: $2,140 · 2025: $1,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,529 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,528.76 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $218.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,240.56 | 2020-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $714.93 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $616.96 | 2020-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $454.34 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $377.93 | 2024-2025 | |
| Ucb, INC. | $314.21 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $308.47 | 2022-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $276.31 | 2022-2023 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $262.21 | 2024 | Siliq, Targretin |
| Regeneron Healthcare Solutions, INC. | $258.98 | 2023-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $240.40 | 2023-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $218.53 | 2021-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $204.37 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $166.91 | 2021-2025 | Ilumya, Winlevi, Blu-U |
| Organon LLC | $97.53 | 2024-2025 | Vtama |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Janssen Scientific Affairs, LLC | $49.31 | 2024 | Tremfya |
| Blueprint Medicines Corporation | $44.45 | 2022-2023 | |
| Incyte Corporation | $36.83 | 2024-2025 | Opzelura, Opzelura |
| Pfizer INC. | $34.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.13 | 2023 | Spevigo |
| Helsinn Therapeutics (U.S.), INC. | $28.00 | 2022 | |
| Mallinckrodt Hospital Products INC. | $26.63 | 2025 | Acthar |
| Smith+Nephew, INC. | $24.85 | 2025 | Grafix Pl |
| Leo Pharma INC. | $21.50 | 2024 | Adbry |
| Biowound Solutions, INC. | $20.93 | 2025 | Bio-Connekt |
| Csl Behring | $16.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Whitman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.